Xencor Inc. Common Stock (XNCR)

About XNCR

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffus…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

260

Website

xencor.com/

Fundamentals

1-day range

$19.93$21.05

Market cap

$1.48B

P/E (trailing)

—

P/E (forward)

-5.94

EPS (trailing)

$-2.17

Dividend yield

—

Beta

0.89

Avg. volume

927.7K

Forecasts

12 analyst ratings

Xencor Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• XNCR

  Xencor Inc. Common Stock

  $26.06

  ▼ 9.76%
  Market cap $1.48BP/E —
  $7.83$30.61
• HROW

  Harrow Inc. Common Stock

  $37.23

  ▼ 3.40%
  Market cap $1.49BP/E —
  $28.54$54.85
• AVBP

  ArriVent BioPharma Inc. Common Stock

  $30.19

  ▼ 2.63%
  Market cap $1.44BP/E —
  $17$35.83
• PAHC

  Phibro Animal Health Corporation Class A Common Stock

  $37.64

  ▲ 3.55%
  Market cap $1.44BP/E 14.51
  $28.25$60.08
• INVA

  Innoviva Inc. Common Stock

  $20.97

  ▲ 0.05%
  Market cap $1.56BP/E 4.21
  $16.52$25.15
• TRAX

  First Tracks Biotherapeutics Inc. Ordinary Shares

  $41.77

  ▼ 6.64%
  Market cap $1.58BP/E —
  $14.72$49.91
• LBRX

  LB Pharmaceuticals Inc Common Stock

  $47.8

  ▼ 0.20%
  Market cap $1.38BP/E —
  $13.36$50.16

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit
  Yahoo · 8/8/2026
• RBC Capital Maintains Outperform on Xencor, Raises Price Target to $20
  Benzinga · 8/6/2026
• Wedbush Maintains Outperform on Xencor, Raises Price Target to $30
  Benzinga · 8/6/2026
• Cantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $44
  Benzinga · 8/6/2026
• Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
  Yahoo · 8/5/2026
• Xencor (NASDAQ:XNCR) Beats Q2 Estimates on Royalty Settlement and Milestone Payment
  ChartMill · 8/5/2026
• Xencor Reports Second Quarter 2026 Financial Results
  Yahoo · 8/5/2026
• Xencor Q2 EPS $(0.29) Beats $(0.79) Estimate, Sales $51.200M Beat $18.922M Estimate
  Benzinga · 8/5/2026

• Ellen Feigal · June 18, 2026 · Sale

  6.8K @ $13.06
• Raymond Joseph Deshaies · June 16, 2026 · Grant

  20.6K
• Raymond Joseph Deshaies · June 16, 2026 · Grant

  10.3K
• Ellen Feigal · June 16, 2026 · Grant

  20.6K
• Ellen Feigal · June 16, 2026 · Grant

  10.3K
• Barbara Klencke · June 16, 2026 · Grant

  20.6K
• Barbara Klencke · June 16, 2026 · Grant

  10.3K
• Kurt A. Gustafson · June 16, 2026 · Grant

  20.6K
• Kurt A. Gustafson · June 16, 2026 · Grant

  10.3K
• Alan Bruce Montgomery · June 16, 2026 · Grant

  20.6K
• Alan Bruce Montgomery · June 16, 2026 · Grant

  10.3K
• Richard J. Ranieri · June 16, 2026 · Grant

  20.6K
• Richard J. Ranieri · June 16, 2026 · Grant

  10.3K
• Todd E. Simpson · June 16, 2026 · Grant

  20.6K
• Todd E. Simpson · June 16, 2026 · Grant

  10.3K

Institutional Ownership

March 31, 2026

Total shares held

80.06M

Total value held

$935.92M

Institutional holders

194